2Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlibidemic rabbits [ J]. Circulation,2001 ; 103 ( 7 ) :993 -9.
4Spindle FG. Matrix metalloproteinases:regulation and dysregulation in the failing heart[ J3. Circ Res,2002 ;90: 520-39.
5Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induetion/activation system exists in the hu/nan left ventricular myocardium and is upregulated in heart failure [ J]. Circulation, 2000; 102 ( 16 ) : 1944-9.
6Creemers EE, Cleutjens JP,Smits JF,et al. Matrix metalloproteinase inhibition after myocardial infarction : A new approach to prevent heart failure [J ] ? Circ Res ,2001 ;89:201-10.
1Kelly RA, Smith TW. Cytokmes and cardiac contractile functitm[J].Circulation, 1997,95(4) :778 - 781.
2Fessel WJ. High uric acid as an indicator of cardiovascular disease, indepencence from obesity[J]. Am J Med,1980,68(3):401 -404.
3Levya F, Anker SD,Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation[J]. Eur Heart J, 1998,19(12) :1746- 1747.
4Visse H, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry[J]. Circ Res, 2003, 92: 827-839.
5Kahari VM, Saarialho Kere U. Matrix metalloproteinase in skin [J]. Exp Dermatol, 1997, 6 (5) : 199-213.
6Ferrans VJ. New insights into the world of matrix metalloproteinases[J]. Circulation, 2002, 105:405-407.
7Yamani MH, Murat TE, Starling RC, et al. Myocardial ischemic injury after heart transplantation is associated with upregulation of vitronectin receptor, activation of the matrix metalloproteinase induction system, and subsequent development of coronary vasculopathy [ J ]. Circulation, 2002,105 : 1955 - 1961.
8Sethi CS, Bailey TA, Luthert PJ, et al. Matrix metalloproteinase biology applied to vitreoretinal disorders [ J ]. Br J Ophthalmol, 2000, 84 : 654 - 666.
9Pei D, Weiss SJ. Furin dependent intracellular avtivation of the human stromelysin-3 zymogen [J]. Nature, 1995, 375:244 - 247.
10Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor ofmatrix metalloproteinases with implications for atherosclerosis [ J]. Clin Invest,2001, 107: 1117-1126.
